人生就是博·(中国区)官方网站

EN
×
EN
  • 业务咨询

    中国:

    Email: marketing@qsdtqr.whjinling.com

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换
Customer Center
客户中心

四价广谱中和双特异性抗体ISH0339的临床前评估通过人生就是博进行

2025-07-10
|
访问量:

ISH0339, a tetravalent bispecific antibody composed of a pair of non-competing neutralizing antibodies that binds specifically to two different neutralizing epitopes of SARS-CoV-2 receptor-binding domain (RBD) and contains an engineered Fc region for prolonged antibody half-life.

ISH0339 bound to SARS-CoV-2 RBD specifically with high affinity and potently blocked the binding of RBD to the host receptor hACE2. ISH0339 demonstrated greater binding, blocking and neutralizing efficiency than its parental monoclonal antibodies, and retained neutralizing ability to all tested SARS-CoV-2 variants of concern. Single dosing of ISH0339 showed potent neutralizing activity for treatment via intravenous injection and for prophylaxis via nasal spray. Preclinical studies following single dosing of ISH0339 showed favorable pharmacokinetics and well-tolerated toxicology profile.

ISH0339 has demonstrated a favorable safety profile and potent anti-SARS-CoV-2 activities against all current variants of concern. Furthermore, prophylactic and therapeutic application of ISH0339 significantly reduced the viral titer in lungs.

Pharmacokinetic analysis of ISH0339

An indirect antigen ELISA assay was used for the detection of ISH0339 in rat serum (Medicilon).

tbad003.pngPharmacokinetic analysis of single-dose ISH0339 administration was conducted by Medicilon.

Extended toxicity study of single-dose ISH0339 was conducted by Medicilon.

Reference:

Huabing Yang, et al. Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection. Antib Ther. 2023 Mar 6;6(2):97-107. doi: 10.1093/abt/tbad003.

相关新闻
×
搜索验证
点击切换